Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Open Access
- 1 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Therapeutics and Clinical Risk Management
- Vol. ume 17, 155-163
- https://doi.org/10.2147/tcrm.s293879
Abstract
Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxia-inducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.Keywords
This publication has 40 references indexed in Scilit:
- Chronic Kidney DiseaseThe Lancet, 2016
- Anaemia in kidney disease: harnessing hypoxia responses for therapyNature Reviews Nephrology, 2015
- Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression AnalysisAmerican Journal of Kidney Diseases, 2013
- Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseThe New England Journal of Medicine, 2009
- Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease PatientsClinical Journal of the American Society of Nephrology, 2009
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaThe New England Journal of Medicine, 2006
- Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2005
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinThe New England Journal of Medicine, 1998